- Investing.com
Allakos Inc. operates as a clinical stage biotechnology company that develops monoclonal antibodies that target immunomodulatory receptors present on the surface of immune effector cells involved in allergy, inflammatory, and proliferative diseases. The company was incorporated in 2012 and is based in San Carlos, California. As of May 15, 2025, Allakos Inc. operates as a subsidiary of Concentra Biosciences, LLC.
AK006 Breakthrough | Explore Allakos's flagship anti-Siglec-6 monoclonal antibody, AK006, showing promising results in Phase 1 trials for chronic spontaneous urticaria treatment |
Financial Resilience | Delve into Allakos's financial strategy, with a cash runway extending into mid-2026, supporting ongoing clinical development amid market volatility |
Market Dynamics | Analyst targets range from $1.40 to $7.00, reflecting diverse views on Allakos's potential in the competitive CSU treatment landscape |
Strategic Horizons | Learn about Allakos's potential for expansion beyond CSU, leveraging AK006's mechanism to address multiple mast cell-mediated disorders |
Metrics to compare | ALLK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALLKPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −0.6x | −0.5x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 0.5x | 2.3x | 2.6x | |
Price / LTM Sales | - | 4.5x | 3.2x | |
Upside (Analyst Target) | 6.4% | 170.0% | 41.2% | |
Fair Value Upside | Unlock | 8.9% | 6.2% | Unlock |